Cochrane · systematic review · CD011408
Haloperidol discontinuation for people with schizophrenia
Essali, A, Turkmani, K, Aboudamaah, S, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Haloperidol discontinuation compared to haloperidol continuation for schizophrenia
Population: schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: clinically important change ‒ not improved (CGI) Haloperidol discontinuation vs haloperidol continuation | RR 2.06 [1.33, 3.2] | 1 study · 49 participants | Very low Downgraded: risk of bias |
Global state: relapse: ‒ Haloperidol discontinuation vs haloperidol continuation | RR 1.8 [1.18, 2.74] | 4 studies · 165 participants | Very low Downgraded: risk of bias |
Mental state: clinically important change in general mental state Haloperidol discontinuation vs haloperidol continuation | no estimate extracted | NR | No studies |
General functioning: clinically important change in general functioning including working ability Haloperidol discontinuation vs haloperidol continuation | no estimate extracted | NR | No studies |
General behaviour: clinically important change in general behaviour Haloperidol discontinuation vs haloperidol continuation | no estimate extracted | NR | No studies |
Quality of life: clinically important change in quality of life Haloperidol discontinuation vs haloperidol continuation | no estimate extracted | NR | No studies |
Satisfaction with treatment: leaving the study early Haloperidol discontinuation vs haloperidol continuation | RR 0.13 [0.01, 2.28] | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |